에 대한 최신 뉴스 Rapid7 (NASDAQ:RPD) 주식

RAPID7 INC

Rapid7

Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.

Rapid7 Inc

Rapid Line Inc

Rapidtron Inc

News

Management

Rapid7 Appoints Marc Brown As Chairman Of The Board; Corey Thomas To Continue As CEO And Board Member

<a href="https://www.sec.gov/Archives/edgar/data/1998597/000090266425002348/xslForm13F_X02/infotable.xml" title="https://www.sec.gov/Archives/edgar/data/1998597/000090266425002348/xslForm13F_X02/infotable.xml">https://www.sec.gov/Archives/edgar/data/1998597/000090266425002348/xslForm13F_X02/infotable.xml</a>

FRPT

TRMB

WOLF

JANA Partners 13F Filing Shows Increased Stake In Lamb Weston By 854,087 Shares; Increased Stake In Markel Group By 47,096 Shares; Increased Stake In Rapid7 By 415,927 Shares; Decreased Stake In Trimble By 232,861 Shares; Sold Complete Stake In Wolfspeed; New Position Of Freshpet With 734,763 Shares

Canaccord Genuity analyst Michael Walkley maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Hold and lowers the price target from $43 to $39.

Price Target

Analyst Ratings

Canaccord Genuity Maintains Hold on Rapid7, Lowers Price Target to $39

Scotiabank analyst Patrick Colville maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Sector Perform and lowers the price target from $38 to $29.

Scotiabank Maintains Sector Perform on Rapid7, Lowers Price Target to $29

Raymond James analyst Adam Tindle maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Outperform and lowers the price target from $45 to $40.

Raymond James Maintains Outperform on Rapid7, Lowers Price Target to $40

Susquehanna analyst Anne Meisner maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Neutral and lowers the price target from $40 to $30.

Susquehanna Maintains Neutral on Rapid7, Lowers Price Target to $30

Morgan Stanley analyst Erin Wilson maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Equal-Weight and raises the price target from $26 to $28.

Morgan Stanley Maintains Equal-Weight on Rapid7, Raises Price Target to $28

Stifel analyst Adam Borg maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Hold and lowers the price target from $38 to $29.

Stifel Maintains Hold on Rapid7, Lowers Price Target to $29

Piper Sandler analyst Rob Owens maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Neutral and lowers the price target from $35 to $30.

Piper Sandler Maintains Neutral on Rapid7, Lowers Price Target to $30

Barclays analyst Saket Kalia maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Equal-Weight and lowers the price target from $26 to $25.

Barclays Maintains Equal-Weight on Rapid7, Lowers Price Target to $25

Analysts' ratings for Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) over the last quarter vary from bullish to bearish, as provided by 19 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">13</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $34.74, a high estimate of $45.00, and a low estimate of $21.00. A 14.09% drop is evident in the current average compared to the previous average price target of $40.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1747141254_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Rapid7 by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$21.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Erin Wilson</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Todd Weller</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$33.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$35.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Erin Wilson</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$33.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$38.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Fatima Boolani</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Adam Tindle</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$36.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Roger Boyd</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$38.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$35.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$35.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Rapid7. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Rapid7 compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Rapid7's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Rapid7's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RPD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Rapid7 analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Rapid7 Better</h2>
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
<h3>Rapid7: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Rapid7 showcased positive performance, achieving a revenue growth rate of 5.36% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Rapid7's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -0.68%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Rapid7's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -25.97%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Rapid7's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.09%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 57.49, Rapid7 faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

19 Analysts Assess Rapid7: What You Need To Know

Rapid7, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) reported better-than-expected earnings for the first <a href="https://www.benzinga.com/quote/RPD/earnings">quarter on Monday</a>.
The company posted quarterly earnings of 49 cents per share which beat the analyst consensus estimate of 35 cents per share. The company reported quarterly sales of $210.25 million which beat the analyst consensus estimate of $208.23 million.
&#8220;We had a slower start to 2025 than anticipated however we have a clear strategy and strong conviction in our long-term opportunity,&#8221; said Corey Thomas, Chairman and CEO of Rapid7. &#8220;Against a more uncertain macroeconomic environment, we are executing with increased focus and urgency—investing behind our leadership in MDR, accelerating Exposure Command adoption, and sharpening our go-to-market engine. We believe these steps position us for improved ARR in the second half of the year and beyond. At the same time, we remain committed to operational discipline and delivering strong free cash flow in 2025.&#8221;
Rapid7 raised its FY2025 adjusted EPS guidance from $1.72-$1.85 to $1.78-$1.91, but lowered its FY2025 sales guidance from $860.00 million-$870.00 million to $853.00 million-$863.00 million.
Rapid7 shares gained 6.4% to close at $26.74 on Monday.
These analysts made changes to their price targets on Rapid7 following earnings announcement.
<ul class="wp-block-list">
<li>DA Davidson analyst Rudy Kessinger downgraded the rating for Rapid7 from Neutral to Underperform and lowered the price target from $29 to $21.</li>
<li>Baird analyst Shrenik Kothari maintained the stock with a Neutral and raised the price target from $26 to $28.</li>
</ul>
Considering buying RPD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image is-resized"><img decoding="async" src="blob:https://editorial.benzinga.com/f2830a14-387a-489c-b143-84b306aefebc" alt="" style="width:660px;height:auto" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Earnings

Trading Ideas

These Analysts Revise Their Forecasts On Rapid7 Following Q1 Results

Baird analyst Shrenik Kothari maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Neutral and raises the price target from $26 to $28.

Baird Maintains Neutral on Rapid7, Raises Price Target to $28

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Compass Point analyst Merrill Ross downgraded the rating for Independence Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>) from Buy to Neutral and announced a $22 price target. Independence Realty Trust shares closed at $19.31 on Monday. <a href="https://www.benzinga.com/quote/IRT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Rudy Kessinger downgraded the rating for Rapid7, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) from Neutral to Underperform and lowered the price target from $29 to $21. Rapid7 shares closed at $26.74 on Monday. <a href="https://www.benzinga.com/quote/RPD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Compass Point analyst Merrill Ross downgraded NexPoint Residential Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>) from Buy to Neutral and slashed the price target from $50 to $42.5. NexPoint Residential shares closed at $37.53 on Monday. <a href="https://www.benzinga.com/quote/NXRT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Daina Graybosch downgraded Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) from Outperform to Market Perform and cut the price target from $5 to $0.39. Affimed shares closed at $0.6930 on Monday. <a href="https://www.benzinga.com/quote/AFMD/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying RPD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142-1024x576.png" alt="" class="wp-image-913351" style="width:633px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142.png 1095w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

Markets

AFMD

NXRT

This Rapid7 Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Piper Sandler raised ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) price target from $9 to $11. Piper Sandler analyst Brent Bracelin maintained a Neutral rating. ZoomInfo shares closed at $10.31 on Monday. <a href="https://www.benzinga.com/quote/ZI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham cut the price target for Annexon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) from $16 to $11. Needham analyst Joseph Stringer maintained a Buy rating. Annexon shares closed at $1.77 on Monday. <a href="https://www.benzinga.com/quote/ANNX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Compass Point slashed NexPoint Residential Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>) price target from $50 to $42.5. Compass Point analyst Merrill Ross downgraded the stock from Buy to Neutral. NexPoint Residential Trust shares closed at $37.53 on Monday. <a href="https://www.benzinga.com/quote/NXRT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson lowered the price target for Rapid7, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) from $29 to $21. DA Davidson analyst Rudy Kessinger downgraded the stock from Neutral to Underperform. Rapid7 shares closed at $26.74 on Monday. <a href="https://www.benzinga.com/quote/RPD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Benchmark slashed the price target for indie Semiconductor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) from $8 to $6. Benchmark analyst Cody Acree maintained a Buy rating. indie Semiconductor shares closed at $2.64 on Monday. <a href="https://www.benzinga.com/quote/INDI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners cut Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) price target from $5 to $0.39. Leerink Partners analyst Daina Graybosch downgraded the stock from Outperform to Market Perform. Affimed shares settled at $0.6930 on Monday. <a href="https://www.benzinga.com/quote/AFMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays increased Stanley Black &amp; Decker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) price target from $69 to $90. Barclays analyst Julian Mitchell upgraded the stock from Equal-Weight to Overweight. Stanley Black &amp; Decker shares closed at $72.53 on Monday. <a href="https://www.benzinga.com/quote/SWK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity cut BILL Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) price target from $105 to $75. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. BILL Holdings shares closed at $47.37 on Monday.  <a href="https://www.benzinga.com/quote/BILL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies increased the price target for Matson, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MATX#NYSE">MATX</a>) from $125 to $135. Jefferies analyst Omar Nokta maintained a Buy rating. Matson shares settled at $113.94 on Monday. <a href="https://www.benzinga.com/quote/MATX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. slashed Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) price target from $50 to $45. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Buy rating. Neurogene shares closed at $17.70 on Monday. <a href="https://www.benzinga.com/quote/NGNE/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying SWK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141-1024x586.png" alt="" class="wp-image-913331" style="width:553px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141.png 1128w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

ANNX

BILL

INDI

MATX

NGNE

Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday

DA Davidson analyst Rudy Kessinger downgrades Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) from Neutral to Underperform and lowers the price target from $29 to $21.

DA Davidson Downgrades Rapid7 to Underperform, Lowers Price Target to $21

Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) is looking for Q2 Adj EPS of $0.43-$0.46 vs $0.35 analyst estimate. sees sales of $211.000 million-$213.000 million vs $208.23 million analyst estimate.

Guidance

Rapid7 Sees Q2 Adj EPS $0.43-$0.46 vs $0.35 Est; Sees Sales $211.000M-$213.000M vs $208.23M Est

Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) raises FY2025 Adj EPS guidance from $1.72-$1.85 to $1.78-$1.91 vs $1.84 analyst estimate. Lowers FY2025 sales outlook from $860.00 million-$870.00 million to $853.00 million-$863.00 million vs $866.33 million estimate.

Rapid7 Raises FY2025 Adj EPS Guidance from $1.72-$1.85 to $1.78-$1.91 vs $1.84 Est; Lowers FY2025 Sales Guidance from $860.00M-$870.00M to $853.00M-$863.00M vs $866.33M Est

Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.35 by 40 percent. This is a 10.91 percent decrease over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $210.25 million which beat the analyst consensus estimate of $208.23 million by 0.97 percent. This is a 2.51 percent increase over sales of $205.10 million the same period last year.

Earnings Beats

Rapid7 Q1 Adj. EPS $0.49 Beats $0.35 Estimate, Sales $210.25M Beat $208.23M Estimate

JP Morgan analyst Brian Essex maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Neutral and lowers the price target from $36 to $29.

Comments

Rapid7

뉴스

에 대한 최신 뉴스 Rapid7 (NASDAQ:RPD) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌